Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Short term Debt (2016 - 2024)

Historic Short term Debt for Protalix BioTherapeutics (PLX) over the last 7 years, with Q2 2024 value amounting to $20.4 million.

  • Protalix BioTherapeutics' Short term Debt changed N/A to $20.4 million in Q2 2024 from the same period last year, while for Jun 2024 it was $20.4 million, marking a year-over-year change of. This contributed to the annual value of $20.3 million for FY2023, which is N/A changed from last year.
  • Per Protalix BioTherapeutics' latest filing, its Short term Debt stood at $20.4 million for Q2 2024.
  • In the past 5 years, Protalix BioTherapeutics' Short term Debt ranged from a high of $56.4 million in Q2 2021 and a low of $3.2 million during Q3 2021
  • Over the past 4 years, Protalix BioTherapeutics' median Short term Debt value was $20.4 million (recorded in 2024), while the average stood at $31.3 million.